Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4G-CAR-GPC3 T cells
- Development stage
- Unknown
- Lead developer
- CARsgen Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
4G-CAR-GPC3 T cells are an autologous fourth-generation chimeric antigen receptor (CAR) T-cell therapy targeting glypican-3 (GPC3), a cell-surface protein highly expressed in hepatocellular carcinoma (HCC). Developed by Carsgen Therapeutics, these cells are engineered to co-express a transcription factor intended to enhance antitumor activity, persistence, and survival within the immunosuppressive solid tumor microenvironment. This fourth-generation construct represents an evolution from earlier second-generation GPC3-targeted CAR-Ts, aiming to overcome the limitations of cell therapy in solid tumors. In clinical settings, 4G-CAR-GPC3 T cells are being investigated for the treatment of advanced, heavily pretreated GPC3-positive HCC, often in combination with tyrosine kinase inhibitors (TKIs) such as sorafenib or regorafenib to potentially synergize and improve objective response rates.
- Other names
- Fourth-generation GPC3-specific CAR-T cells4G-CAR-GPC3 T cell therapy
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on 4G-CAR-GPC3 T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4G-CAR-GPC3 T cells.